Electrical Research in Oncology

Electrical activity is one way to study living tissue, but an electrical measurement is not automatically a cancer diagnostic. Membrane voltage and ion-channel behavior are subjects of basic research. Levin and Martyniuk's review discusses bioelectric patterning in development; it does not establish a patient-level tumor fingerprint.

A specific clinical example

Tumor Treating Fields (TTFields) are alternating electric fields delivered through scalp arrays. In the EF-14 randomized trial , 695 people with newly diagnosed glioblastoma after radiochemotherapy were assigned maintenance temozolomide with or without TTFields (200 kHz, at least 18 hours daily). Median overall survival from randomization was 20.9 versus 16.0 months. The comparison was an addition to chemotherapy, not a drug-free replacement.

Questions that remain

Those results belong to that cancer, treatment setting and delivery method. They do not demonstrate that electrical profiling can choose a treatment for another tumor, or that PEMF, heating or nanoparticle delivery achieves the same result. A proposed profiling workflow would first need reproducible measurements and evidence that decisions based on them improve outcomes. Until then, tumor-specific electrical measurements are a research question, not a prescription.

From tumor electrical properties to a defined cancer study Study electrical properties in defined tumor models

Keep developmental observations separate from clinical diagnosis

Test a specified intervention in a specified cancer

What the linked references do not establish: The linked glioblastoma TTFields trial and bioelectric-code review do not validate Electrome tumor profiling or AI-guided treatment.